A detailed history of Pro Share Advisors LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 21,130 shares of IDYA stock, worth $586,780. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,130
Previous 13,920 51.8%
Holding current value
$586,780
Previous $488,000 37.09%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$30.37 - $43.05 $218,967 - $310,390
7,210 Added 51.8%
21,130 $669,000
Q2 2024

Aug 13, 2024

SELL
$34.37 - $43.46 $107,474 - $135,899
-3,127 Reduced 18.34%
13,920 $488,000
Q1 2024

May 08, 2024

BUY
$34.2 - $47.13 $101,437 - $139,787
2,966 Added 21.06%
17,047 $748,000
Q4 2023

Feb 14, 2024

BUY
$24.59 - $35.83 $80,286 - $116,984
3,265 Added 30.19%
14,081 $501,000
Q3 2023

Nov 13, 2023

BUY
$21.07 - $29.77 $990 - $1,399
47 Added 0.44%
10,816 $291,000
Q2 2023

Aug 10, 2023

BUY
$13.33 - $25.53 $143,550 - $274,932
10,769 New
10,769 $253,000
Q2 2022

Aug 01, 2022

SELL
$8.28 - $13.88 $83,835 - $140,535
-10,125 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$11.18 - $24.02 $27,402 - $58,873
-2,451 Reduced 19.49%
10,125 $114,000
Q4 2021

Feb 08, 2022

BUY
$20.95 - $26.88 $3,645 - $4,677
174 Added 1.4%
12,576 $297,000
Q3 2021

Nov 12, 2021

SELL
$17.26 - $27.08 $13,687 - $21,474
-793 Reduced 6.01%
12,402 $316,000
Q2 2021

Aug 13, 2021

BUY
$17.76 - $24.83 $79,120 - $110,617
4,455 Added 50.97%
13,195 $277,000
Q1 2021

May 14, 2021

BUY
$13.48 - $23.77 $117,815 - $207,749
8,740 New
8,740 $205,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.33B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.